You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
The latest news on next-generation sequencing.
FoundationOne Liquid CDx can now be used as a companion diagnostic for therapies to treat advanced ovarian, breast, and non-small cell lung cancer.
The test analyzes substitutions, insertion and deletion alterations, and copy number alterations in 324 genes, along with some genomic signatures in solid tumors.
Using RNA and DNA sequencing to predict tumor site and detect gene alterations may allow patients with CUP to receive appropriate targeted treatment.
The recently launched BRCA Care program may increase test access in six countries, though it cannot ensure access to downstream interventions based on results.
The findings demonstrate the value of multi-cohort platform trials as an option for refractory cancer patients with particularly rare genomic tumor alterations.
The firm will conduct genomic and transcriptomic analysis to identify predictors of response to the personalized immunotherapy TG4050.
The study, supported by TargetCancer, Foundation Medicine, and Bayer, aims to match 400 patients with rare cancers to personalized treatments based on NGS.
The randomized trial will assess the glutaminase inhibitor plus standard-of-care versus standard-of-care alone in patients with KEAP1- or NRF2-mutated tumors.
A secondary analysis suggested that using NGS to identify patients with PTEN loss may be better than IHC in identifying best responders to treatment.
The deal, which was approved by the boards of directors of both companies, is expected to close in the second half of 2021, pending customary conditions.